FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A

Transplantation

Volumn 75, Issue 7, 2003, Pages 945-952

  Koshiba, Takaaki ^a   Van Damme, Boudewijn ^a   Rutgeerts, Omer ^a   Waer, Mark ^a   Pirenne, Jacques ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYCLOSPORIN A; FINGOLIMOD; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; CHRONIC DISEASE; COMPLEMENT FIXATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOGLOBULIN DEPOSITION; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; LYMPHOCYTE TRANSFER; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; VASCULAR ENDOTHELIUM;

EID: 0344806941     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000058469.38572.10     Document Type: Article

References (36)

1. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
2. Otsuka M, Yuzawa K, Takada Y, et al. Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. Nephron 2001; 88: 144.
3. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365.
4. Orloff MS, DeMara EM, Coppage ML, et al. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation 1995; 59: 282.
5. Shirwan H. Chronic allograft rejection: Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role? Transplantation 1999; 68: 715.
6. Fujuta T, Inoue K, Yamamoto S, et al. Fungal metabolites: B. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994; 47: 208.
7. Adachi K, Kohara T, Nakano N, et al. Design, synthesis, and structureactivity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem 1995; 5: 853.
8. Brinkmann V, Pinschewer D, Chiba K, et al. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000; 21: 49.
9. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037.
10. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200.
11. Enosawa S, Suzuki S, Kakefuda T, et al. Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. Immunopharmacology 1996; 34: 171.
12. Chiba K, Hoshino Y, Suzuki C, et al. A novel immunosuppressant possessing unique mechanism: Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996; 28: 1056.
13. Tedesco H, Kahan B, Mourad G, et al. FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection in renal allograft recipients (interim data). Am J Transplant 2001; l(suppl): 243.
14. Vaessen LMV, Lameijer LDF, Carpenter CB, et al. The R1-rat: A new RT1 haplotype. Transplant Proc 1979; 11: 1565.
15. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
16. Koshiba T, Ji P, Tanaka K, et al. Tolerance induction with FTY720 and donor-specific blood transfusion: Discrepancy between heart transplantation and intestinal transplantation. Transplant Proc 2000; 32: 1255.
17. Mottram P, Raisanen-Sokolowski A, Glysing-Jensen T, et al. Redefining peripheral tolerance in the BALB/C to CBA mouse cardiac allograft model. Transplantation 1998; 66: 1510.
18. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
19. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000;70:1098.
20. Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol 1999; 163: 1010.
21. Pelletier RP, Hennessy PK, Admas PW, et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney of kidney-pancreas transplantation. Am J Transplant 2002; 2: 134.
22. Tilney NL, Whitley WD, Diamond JR, et al. Chronic rejection - an undefined conundrum. Transplantation 1991; 52: 389.
23. Xu M, Pirenne J, Antoniou S, et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. Transplant Proc 1998; 30: 2221.
24. Nikolova Z, Hof A, Rudin M, et al. Prevention of graft vessel disease by combined FTY720/cyclosporine: A treatment in a rat carotid artery transplantation model. Transplantation 2000; 69: 2525.
25. Pober JS. Aortic interposition grafts: A model of rejection or rejection of the model? Am J Transplant 2002; 2: 201.
26. Le Moine A, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest 1999; 103: 1659.
27. Nolan CR, Saenz KP, Thomas CA III, et al. Role of the eosinophil in chronic vascular rejection of renal allografts. Am J Kidney Dis 1995; 26: 634.
28. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97: 833.
29. Ziai F, Nagano H, Kusaka M, et al. Renal allograft protection with losartan in Fisher-〉Lewis rats: Hemodynamics, macrophages, and cytokines. Kidney Int 2000; 57: 2618.
30. Koshiba T, Giulietti A, Van Damme B, et al. Paradoxical early upregulation of intragraft Th1 cytokines is associated with graft acceptance following donor-specific blood transfusion. Transplant Int 2003 (in press).
31. Dallman MJ, Morris PJ. In: Morris PJ, ed. Kidney transplantation: Principles and practice [ed 4]. Philadelphia, WB Saunders 1994, p 8.
32. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051.
33. Xu M, Pirenne J, Antoniou EA, et al. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transpl Int 1998; 11: 288.
34. Chueh SC, Chen JR, Chen J, et al. FTY720 prevents chronic rejection of rat heterotopic cardiac allografts. Transplant Proc 2001; 33: 542.
35. White E, Hildemann WH, Mullen Y. Chronic kidney allograft reactions in rats. Transplantation 1969; 8: 602.
36. Myers BD, Newton L, Boshkos C, et al. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 1988; 46: 694.